Loading
Latest filing published 17 Nov 2025 for Perspective Therapeutics, Inc., €19k.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
This profile gathers the share dealings of Jonathan Robert Hunt in Perspective Therapeutics, Inc., where the filings describe the role as finance chief. We count 14 filings; the first trade dates from 22 October 2020 and the latest from 13 November 2025.
Every open-market trade on record is a purchase: 14 purchases worth €215k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2025 to date brings 1 purchase and no sales.
A typical purchase (the median) is worth €16k. Clusters matter here: 14 out of 14 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
The latest filing, published on 17 November 2025, reports an open-market purchase of €19k in Perspective Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations